|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ELN |
Gene summary for ELN |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ELN | Gene ID | 2006 |
| Gene name | elastin | |
| Gene Alias | ADCL1 | |
| Cytomap | 7q11.23 | |
| Gene Type | protein-coding | GO ID | GO:0003007 | UniProtAcc | P15502 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2006 | ELN | P4T-E | Human | Esophagus | ESCC | 1.70e-06 | 2.68e-01 | 0.1323 |
| 2006 | ELN | P8T-E | Human | Esophagus | ESCC | 2.96e-08 | 3.28e-01 | 0.0889 |
| 2006 | ELN | P10T-E | Human | Esophagus | ESCC | 2.23e-13 | 3.04e-01 | 0.116 |
| 2006 | ELN | P12T-E | Human | Esophagus | ESCC | 6.44e-09 | 2.72e-01 | 0.1122 |
| 2006 | ELN | P16T-E | Human | Esophagus | ESCC | 5.32e-12 | 3.79e-01 | 0.1153 |
| 2006 | ELN | P19T-E | Human | Esophagus | ESCC | 9.01e-04 | 8.91e-01 | 0.1662 |
| 2006 | ELN | P21T-E | Human | Esophagus | ESCC | 4.36e-08 | 3.05e-01 | 0.1617 |
| 2006 | ELN | P22T-E | Human | Esophagus | ESCC | 2.01e-02 | -8.46e-03 | 0.1236 |
| 2006 | ELN | P27T-E | Human | Esophagus | ESCC | 7.13e-19 | 5.63e-01 | 0.1055 |
| 2006 | ELN | P56T-E | Human | Esophagus | ESCC | 1.62e-04 | 4.04e-01 | 0.1613 |
| 2006 | ELN | P57T-E | Human | Esophagus | ESCC | 2.53e-11 | 4.89e-01 | 0.0926 |
| 2006 | ELN | P62T-E | Human | Esophagus | ESCC | 9.07e-17 | 6.91e-01 | 0.1302 |
| 2006 | ELN | P65T-E | Human | Esophagus | ESCC | 1.75e-46 | 1.69e+00 | 0.0978 |
| 2006 | ELN | P74T-E | Human | Esophagus | ESCC | 2.43e-37 | 1.49e+00 | 0.1479 |
| 2006 | ELN | P76T-E | Human | Esophagus | ESCC | 2.38e-02 | 7.25e-03 | 0.1207 |
| 2006 | ELN | P79T-E | Human | Esophagus | ESCC | 5.88e-06 | 2.36e-01 | 0.1154 |
| 2006 | ELN | S014 | Human | Liver | HCC | 5.48e-15 | 6.72e-01 | 0.2254 |
| 2006 | ELN | S015 | Human | Liver | HCC | 2.28e-13 | 6.75e-01 | 0.2375 |
| 2006 | ELN | S016 | Human | Liver | HCC | 4.21e-13 | 6.76e-01 | 0.2243 |
| 2006 | ELN | ATC13 | Human | Thyroid | ATC | 2.62e-100 | 2.42e+00 | 0.34 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0010976 | Liver | HCC | positive regulation of neuron projection development | 88/7958 | 163/18723 | 1.98e-03 | 1.00e-02 | 88 |
| GO:003003822 | Liver | HCC | contractile actin filament bundle assembly | 60/7958 | 106/18723 | 2.34e-03 | 1.16e-02 | 60 |
| GO:004314922 | Liver | HCC | stress fiber assembly | 60/7958 | 106/18723 | 2.34e-03 | 1.16e-02 | 60 |
| GO:00507674 | Liver | HCC | regulation of neurogenesis | 181/7958 | 364/18723 | 3.00e-03 | 1.40e-02 | 181 |
| GO:0060999 | Liver | HCC | positive regulation of dendritic spine development | 27/7958 | 42/18723 | 3.60e-03 | 1.60e-02 | 27 |
| GO:00507693 | Liver | HCC | positive regulation of neurogenesis | 116/7958 | 225/18723 | 3.67e-03 | 1.63e-02 | 116 |
| GO:00510913 | Liver | HCC | positive regulation of DNA-binding transcription factor activity | 131/7958 | 260/18723 | 5.98e-03 | 2.45e-02 | 131 |
| GO:006099611 | Liver | HCC | dendritic spine development | 54/7958 | 99/18723 | 1.03e-02 | 3.86e-02 | 54 |
| GO:00420631 | Liver | HCC | gliogenesis | 148/7958 | 301/18723 | 1.10e-02 | 4.07e-02 | 148 |
| GO:0050775 | Liver | HCC | positive regulation of dendrite morphogenesis | 23/7958 | 37/18723 | 1.25e-02 | 4.53e-02 | 23 |
| GO:001635811 | Liver | HCC | dendrite development | 121/7958 | 243/18723 | 1.26e-02 | 4.56e-02 | 121 |
| GO:00609981 | Liver | HCC | regulation of dendritic spine development | 35/7958 | 61/18723 | 1.35e-02 | 4.82e-02 | 35 |
| GO:1902903210 | Thyroid | ATC | regulation of supramolecular fiber organization | 210/6293 | 383/18723 | 6.20e-18 | 7.54e-16 | 210 |
| GO:0043254210 | Thyroid | ATC | regulation of protein-containing complex assembly | 225/6293 | 428/18723 | 2.72e-16 | 2.33e-14 | 225 |
| GO:0032970210 | Thyroid | ATC | regulation of actin filament-based process | 208/6293 | 397/18723 | 5.82e-15 | 3.80e-13 | 208 |
| GO:0007015210 | Thyroid | ATC | actin filament organization | 227/6293 | 442/18723 | 5.96e-15 | 3.85e-13 | 227 |
| GO:0032956210 | Thyroid | ATC | regulation of actin cytoskeleton organization | 190/6293 | 358/18723 | 1.73e-14 | 1.01e-12 | 190 |
| GO:005125829 | Thyroid | ATC | protein polymerization | 159/6293 | 297/18723 | 9.33e-13 | 3.96e-11 | 159 |
| GO:0110053210 | Thyroid | ATC | regulation of actin filament organization | 150/6293 | 278/18723 | 1.82e-12 | 7.58e-11 | 150 |
| GO:003253526 | Thyroid | ATC | regulation of cellular component size | 191/6293 | 383/18723 | 2.51e-11 | 8.69e-10 | 191 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ELN | SNV | Missense_Mutation | novel | c.418N>G | p.Lys140Glu | p.K140E | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.987) | TCGA-A2-A3XS-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD | |
| ELN | SNV | Missense_Mutation | rs782282589 | c.343N>A | p.Val115Ile | p.V115I | protein_coding | tolerated_low_confidence(0.07) | benign(0.003) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| ELN | SNV | Missense_Mutation | c.178G>C | p.Gly60Arg | p.G60R | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.776) | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| ELN | SNV | Missense_Mutation | c.1519N>C | p.Gly507Arg | p.G507R | protein_coding | deleterious_low_confidence(0) | benign(0.239) | TCGA-AR-A0TP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| ELN | SNV | Missense_Mutation | novel | c.1900N>G | p.Gln634Glu | p.Q634E | protein_coding | unknown(0) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| ELN | SNV | Missense_Mutation | c.1897T>C | p.Ser633Pro | p.S633P | protein_coding | unknown(0) | TCGA-E9-A247-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| ELN | SNV | Missense_Mutation | c.1546N>A | p.Pro516Thr | p.P516T | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-LL-A441-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | ||
| ELN | insertion | Nonsense_Mutation | novel | c.1847_1848insCACACAGCAAATCTATGCCAGGGCCGAGGCTCCAGCCCTCTTTCCATA | p.Gly616_Val617insThrGlnGlnIleTyrAlaArgAlaGluAlaProAlaLeuPheProTer | p.G616_V617insTQQIYARAEAPALFP* | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | |||
| ELN | insertion | In_Frame_Ins | novel | c.609_610insGCTACTTGGGAGGCTGAGGCAGGAGGATTG | p.Pro203_Leu204insAlaThrTrpGluAlaGluAlaGlyGlyLeu | p.P203_L204insATWEAEAGGL | protein_coding | TCGA-A2-A0EX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |||
| ELN | insertion | In_Frame_Ins | novel | c.903_904insCTCCAT | p.Pro301_Ala302insLeuHis | p.P301_A302insLH | protein_coding | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2006 | ELN | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | PRT-201 | VONAPANITASE | ||
| 2006 | ELN | DRUGGABLE GENOME, CLINICALLY ACTIONABLE | CHEMBL3545070 | VONAPANITASE |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |